Abstract
A large, randomised control trial known as PLATO study proved a turning point in the assessment of superiority of ticagrelor over clopidogrel in post- MI cases. This breakthrough in assessing the quantum of efcacy of ticagrelor over clopidogrel in post-MI patients led to changes in international guidelines. However, based on the mortality index associated with these two drugs, the outcome is not encouraging, and both ticagrelor and clopidogrel are on par in terms of efcacy or safety. Recurrent episodes of bleeding were more common in patients who were prescribed ticagrelor than in patients who were given clopidogrel. However, future trials with longer follow-up time periods may be able to answer all the remaining questions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
